CCR8

Product List

Creative Biolabs has a long history of providing high-quality services and products to provide customers with reliable support for CAR-T cell therapy research. Please browse the following CCR8 CAR-related products that we can provide.

Background

CCR8 is a chemokine receptor that is specifically highly expressed on tumor-infiltrating regulatory T cells (Tregs) and is also expressed in Th2 cells and tumor cells, but is rarely expressed on peripheral blood Treg or normal tissues. CCR8 is involved in the recruitment of Treg and Th2 cells to inflammation and tumor sites, and its high expression is associated with a variety of cancers, including colorectal cancer, breast cancer, gastric cancer, metastatic brain cancer, metastatic liver cancer, etc., and is considered to be a potential specific marker of Treg at tumor sites and a promising tumor immune target. Studies have shown that the development of monoclonal antibody drugs targeting CCR8 is beneficial for the specific inhibition of the function of Treg at tumor sites, which is helpful for cancer treatment.

Fig.1 Location of CCR8 on tumor Treg cells.¹

Associated Diseases

Ovarian Cancer

Colorectal Cancer

Breast Cancer

Gastric Cancer

Metastatic Brain Cancer

Metastatic Liver Cancer

Anti-CCR8 CAR-T Services

Anti-CCR8 CAR-T In Vitro Assays

Anti-CCR8 CAR-T Expression Test

Creative Biolabs provides in vitro expression and function studies of anti-CCR8 CAR T cells. The figure below investigates whether CCR8 CAR T cells inhibit T cell function. The results showed that there were differences in the expression level of CCR8 in different CAR construction methods.

Fig.2 Detection of the expression of CCR8 CAR T cells by flow cytometry.²

Anti-CCR8 CAR-T Cytokine Release Test

Creative Biolabs provides in vitro cytokine release assays for anti-CCR8 CAR T cells. As shown in Figure 2, we provide a multiplex immunoassay to analyze the concentration of indicator cytokines in the CCR8 CAR T cell supernatant.

Fig.3 The levels of granzyme-B and IFN-γ in CCR8 CAR T cell were determined by ELISA.²

Anti-CCR8 CAR-T In Vitro Cytotoxicity Assay

Creative Biolabs offers in vitro cytotoxicity testing services for anti-CCR8 CAR T cells. As shown in Figure 4, cytotoxicity assays were performed on different construct CCR8 CAR T cells in the ATLL cell line, and the results showed that C1028z and C1928z T exhibited higher cytotoxicity.

Fig.4 Cytolytic activity of anti-CCR8 CAR-T in ATLL cell lines.²

Anti-CCR8 CAR-T In Vivo Assays

Anti-CCR8 CAR-T Cell Therapy Animal Models

The selection of appropriate animal models provides a scientific basis for the preclinical study of CCR8 CAR-T therapy. Creative Biolabs offers a variety of animal models for in vivo CCR8 CAR-T studies, such as immunodeficient NSI mice, which have been used in several articles. At the same time, the in vivo efficacy of CCR8 CAR-T was evaluated by using bioluminescence imaging (BLI) and other methods to detect the required indicators in the model.

Fig.5 Schematic diagram of in vivo model construction of anti-CCR8 CAR-T cells.²

Efficacy Test of Anti-CCR8 CAR-T

Creative Biolabs provides in vivo efficacy evaluation services to customers based on suitable animal models. As shown in Figure 6, CCR8 CAR T cells have excellent results in prolonging survival.

Fig.6 Growth curves of mouse tumors treated with CCR8 CAR T cells.³

References

1. Moser, Bernhard. "Chemokine receptor-targeted therapies: Special case for CCR8." Cancers. (2022) 14,3 511.
2. Zheng, Diwei.; et al. "The chemokine receptor CCR8 is a target of chimeric antigen T cells for treating T cell malignancies." Frontiers in immunology. (2022) 13 808347.
3. Cadilha, B.L.; et al. "Combined tumor-directed recruitment and protection from immune suppression enable CAR T cell efficacy in solid tumors." Science advances. (2021) 7,24 eabi5781.